Author

Susanna Suh

OpenAlex ID: A5041266264

A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

2021 · Joseph McGuirk, Carlos R. Bachier, et al. · Journal of Clinical Oncology · 26

Works count: 1

Citation count: 26

H-index: 1

I10-index: 1